Macrogen said Monday that it has agreed with Exosome Plus to receive exclusively the latter’s Exo2DTM, an exosome separation kit. The two companies also signed a memorandum of understanding to develop new exosome-based diagnostic methods and treatment.
|Macrogen CEO Yang Kap-seok (left) and Exosome Plus CEO Boo Jong-wook shake hands after signing a business agreement, at Macrogen headquarters in Gasan-dong, southwestern Seoul, on Friday.|
Under the accord, Exosome Plus will supply its high-efficiency exosome separation kit to Macrogen exclusively in the next year. Also, Macrogen may sell the separation kit it bought to a third party.
Macrogen said it plans to increase production efficiency and service stability for its exosome nucleic acid analysis service with Exosome’s separation kit, while also generating additional revenue by selling the separation kit using its distribution network.
The two companies also plan to cooperate on developing early disease diagnosis markers, disease treatment drugs, and application fields such as drug delivery, vaccines, and cosmetics, through the MoU.
“Macrogen is a leader in the domestic exosome market as it has the technology to provide high-quality nucleic acid analysis results with only a small amount of exosome,” Exosome Plus CEO Boo Jong-wook said. “We expect that the combination of our high-purity exosome separation technology with Macrogen's nucleic acid analysis technology will provide more accurate and efficient services to researchers.”
Macrogen CEO Yang Kap-seok also said, “Exosome is an industry that has high potential as its scope of application is rapidly expanding due to diagnosis, treatment, and pharmaceuticals. We intend to advance into the exosome-based biopharmaceutical market by strengthening our partnership with Exosome Plus, which boasts outstanding market competitiveness in the separation and quality control of exosome.